Meta Platforms Price Target Raised, September 22 2026
Meta Platforms drew the heaviest analyst traffic Tuesday morning, four desks in all. Its new AI agent, Muse, hit the top of the U.S. free iPhone app chart over the weekend. Travere Therapeutics and MetLife rounded out the day’s three most-covered names. One drew two reiterations. The other drew a single upgrade.
Meta Platforms (META)
Meta owns Facebook, Instagram, WhatsApp and Messenger. It sells advertising against all four. It has spent the last two years pushing into generative AI. That push covers both a consumer product line and an ad-targeting tool for its advertiser base. Second-quarter revenue reached $60.8 billion, a 28 percent increase from a year earlier. Full-year 2025 revenue came to $201.0 billion, with net income of $60.5 billion. Muse is the newest piece of the AI push. It’s an agent app, and it reached the No. 1 spot on Apple’s free app chart this weekend. Chipmaker AMD crossed a $1 trillion market capitalization Monday on the same wave of investor interest. The move ties to bets that AI agents will lift demand for the chips that run them.
Four analysts weighed in on Meta Tuesday. Jefferies‘ Brent Thill kept his Buy rating. He raised his price target from $710 to $875, the largest move of the day. Mizuho‘s Lloyd Walmsley reiterated Outperform at $750. B of A Securities‘ Justin Post reiterated Buy at $810. StoneX‘s Mark Zgutowicz held the lone non-Buy view among the four. He reiterated Hold.
Meta: the track record behind today’s calls
Thill’s own history on Meta gives his raise some weight to lean on. AnaChart records 44 analysts on Meta over the last twelve months. Their average target sits at $801.73. That’s a $128.13 premium to Monday’s close. Ronald Josey of Citi has hit 50 of 57 prior Meta calls (87.72%). His own target sits at $800, close to Thill’s new number, with an average potential upside of 18.82%. Barton Crockett of Rosenblatt carries a bolder standing target, $886, with a record of 16 of 38 (42.11%) and a 31.59% average upside. Meta’s rating mix runs 91.46% Buy, 7.83% Hold and 0.71% Sell. The average Meta price target takes 213 days to be reached, and the board’s own hit rate for the stock sits at 85.68%.
Travere Therapeutics (TVTX)
Travere is a clinical-stage biopharmaceutical company focused on rare kidney diseases. Its lead approved product, FILSPARI (sparsentan), treats IgA nephropathy and focal segmental glomerulosclerosis, both rare kidney disorders. Second-quarter total revenue reached $169.6 million. FILSPARI sales made up $141.1 million of that, a 96 percent increase from a year earlier, with the balance split between Tiopronin products and license and collaboration revenue. The FSGS indication is the newer of the two, and management has pointed to it as the larger of the two long-term opportunities. The company disclosed Monday that CEO Eric Dube plans to step down from the role. The board has not named a permanent replacement yet. Travere shares closed at $62.86 Monday, according to AnaChart’s board.
No rating changed on Travere Tuesday. Two analysts reiterated existing views. Wedbush‘s Laura Chico reiterated Outperform. She held her $76 target. HC Wainwright & Co.‘s Joseph Pantginis reiterated Buy and held his $67 target.
Travere: the track record behind today’s calls
Chico’s record on this name is strong. Her 20 of 21 prior calls have hit. That’s a 95.24% ratio, with an average 20.10% upside per call. Liisa Bayko of Evercore carries the Street-high target among Travere’s most recent analysts, $78, with 8 of 10 calls landing (80%) and a 28.10% average upside. Tyler Van Buren of TD Cowen sits close behind, with 8 of 9 calls landing (88.89%) and a $75 target of his own. Vamil Divan of Guggenheim also holds a $75 target. His record runs 7 of 8 (87.5%). AnaChart records 11 analysts on Travere over the last twelve months. Their average target comes to $55.50. The stock’s rating mix runs 90% Buy and 10% Hold. The average Travere target takes 434.66 days to be reached.
MetLife (MET)
MetLife sells insurance and financial products. Its lines include life insurance, dental and disability coverage, and retirement and annuity products, sold to individuals and employers, with operations spanning the U.S., Latin America, Asia, Europe and the Middle East. Premiums, fees and other revenues reached $13.7 billion in the second quarter, up 7% from a year earlier. Second-quarter revenue came to $19.15 billion. Adjusted earnings per share hit $2.43, seven cents above the $2.36 analyst consensus, and the company disclosed a $3 billion share buyback alongside the results.
Only a single analyst moved on MetLife Tuesday morning. Piper Sandler‘s Paul Newsome upgraded the stock from Neutral to Overweight. He raised his price target from $99 to $110.
MetLife: the track record behind today’s calls
Nigel Dally of Morgan Stanley carries the Street-high target on MetLife among its five most recent analysts, $111, backed by a 36 of 38 record (94.74%) and a 15.37% average upside. Alex Scott of Barclays has a 21 of 21 record here (100%). His $97 target sits close to where the stock trades now. Ryan Krueger of Stifel carries a $108 target, with 11 of 13 calls landing (84.62%). Wesley Carmichael of Wells Fargo holds a $109 target. His record here is thinner, 3 of 5 calls (60%). He only initiated the name in February. AnaChart records 15 analysts on MetLife over the last twelve months. Their average target comes to $97.85, a 1.25% premium to Monday’s close. The stock’s rating mix runs 88.37% Buy and 11.63% Hold.
Every price target above is scored the same way across 9,600 tickers, reached or not reached. The full file, updated daily, is available for download at the AnaChart store, alongside the underlying ratings history for every analyst named above. Each figure comes from the analyst’s own published note, matched against AnaChart’s record of whether that call was eventually met.
Monday’s set of analyst calls, on a different set of tickers, are in the September 21 update.
